Filing Details
- Accession Number:
- 0000899243-21-034627
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-31 19:06:18
- Reporting Period:
- 2021-08-27
- Accepted Time:
- 2021-08-31 19:06:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1435049 | Chinook Therapeutics Inc. | KDNY | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1745960 | Versant Voyageurs I, L.p. | One Sansome Street Suite 3630 San Francisco CA 94104 | No | No | Yes | No | |
1745961 | Versant Voyageurs I Parallel, L.p. | One Sansome Street Suite 3630 San Francisco CA 94104 | No | No | Yes | No | |
1750266 | Versant Venture Capital Vii, L.p. | One Sansome Street Suite 3630 San Francisco CA 94104 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-08-27 | 510,000 | $14.00 | 4,223,023 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-08-27 | 261,902 | $14.00 | 2,171,197 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2021-08-27 | 78,098 | $14.00 | 644,149 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
- These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
- These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.